RXi Pharmaceuticals has parlayed a chunk of its penny OTC stock for a portfolio of RNAi therapies at OPKO Health. In the deal RXi agreed to hand over 50 million shares--worth about $10 million--to RXi along with a commitment of up to $50 million more in milestones.
RXi Pharmaceuticals will use a new government grant to pursue preclinical work on an RNAi-related treatment for a nasty form of eye cancer. The news underscores the fact that research in the field is advancing, even as progress toward development of new RNAi treatments continues to be frustrating and sluggish.
Frustrated by the slow progress of RNAi technology, RXi Pharmaceuticals ($RXII) announced this morning that it will split its work, changing its name to Galena BioPharma and retaining a focus on
Worcester, MA-based RXi Pharmaceuticals has licensed an ovarian cancer vaccine from The University of Texas MD Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military
RXi Pharmaceuticals has announced the FDA lifted a Chemistry, Manufacturing and Controls (CMC) partial clinical hold that delayed Phase III trials of the company's vaccine. The developer initiated a
With its lead therapy not yet in the clinic, RNAi pioneer RXi has engineered the takeover of Apthera for a chunk of stock and replaced its CEO with one of its board members. And the merger--which
EyeGate Pharma, which is involved in a Phase III study of its lead product, EGP-437, for the treatment of dry eye syndrome, has announced that it will collaborate with RXi Pharmaceuticals for ocular
Three philanthropic organizations dedicated to finding a treatment for ALS, also known as Lou Gehrig's Disease, have financed a new collaboration between RXi Pharmaceuticals and University of
CytRx's affiliate RXi Pharmaceuticals has licensed exclusive rights to technology that could allow for the oral delivery of RNAi therapeutics. CytRx says the technology, which was licensed from the